Eculizumab for a catastrophic relapse in NMOSD: case report.

Autores de IIS La Fe

• David Gorriz Romero

  Autor

• Francisco Carlos Pérez Miralles

  Autor

• Carlos Quintanilla Bordas

  Autor

• María Del Carmen Alcalá Vicente

  Autor

• Marina Frasquet Carrera

  Autor

• Bonaventura Casanova Estruch

  Autor

Grupos

• Investigación en Neuroinmunología y Esclerosis Múltiple

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) are a group of inflammatory disorders of central nervous system characterized by immune-mediated demyelination and axonal damage, predominantly affecting spinal cord and optic nerves. This case report describes a 47-year-old woman with an aggressive form of seropositive NMOSD who had previously been treated with corticosteroids, plasma exchange, and cyclophosphamide. She experienced a life-threatening relapse that did not respond to conventional treatment, but ultimately showed a positive response to eculizumab. Furthermore, we describe the role of sNfL.

© 2023. Fondazione Società Italiana di Neurologia.

Keywords

• Central nervous system; Eculizumab; Immune-mediated demyelination; Neuromyelitis optica spectrum disorders